Phase 2 Endometrial Cancer Trial, Recruiting NCT07276360 Sponsor: Uganda Cancer Institute Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT07276360
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You have been diagnosed with a specific type of cervical cancer (squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma) confirmed by a tissue test, and have not yet received any treatment for it
  • Your cancer has been staged using the FIGO 2018 system as stage IB3, IIA, IIB, IIIA, IIIB, or IIIC
  • You are able to give written consent in English, Luganda, Runyankole, or Lango
  • You are willing to attend follow-up appointments for up to 12 months after treatment
  • Your doctors consider you well enough to receive a chemotherapy drug called cisplatin
  • You are generally able to carry out basic daily activities (your doctors will assess this using a standard scale)
  • Your blood test results meet certain minimum levels for white blood cells, platelets, red blood cells, and kidney and liver function (confirm with trial site)
  • If you are HIV-positive, you have been on a stable HIV treatment (antiretroviral therapy) for at least 6 weeks before joining

Who may not be able to join:

  • You have previously had your womb (uterus) removed, either fully or partially (hysterectomy)
  • There is evidence that your cancer has spread to distant parts of your body
  • You have previously had radiotherapy to your pelvis or abdomen
  • You have metal hip replacements on both sides that could interfere with radiotherapy
  • You have a history of inflammatory bowel disease or another condition that could cause complications with radiotherapy (confirm with trial site)
  • You are pregnant at the time of joining the trial
  • You currently have another active cancer that is not being treated
  • You have an uncontrolled medical or mental health condition that would make it difficult to follow the trial requirements (confirm with trial site)
  • You are HIV-positive with an uncontrolled infection, specifically a viral load above 2,000 copies/mL
  • Your CD4 count (a measure of immune system health) is below 200 cells/mm³

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Solomon Kibudde, MBChB, MMed., Uganda Cancer Institute

Phone: +256773004608

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Uganda Cancer Institute
Registry
ClinicalTrials.gov
Start date
11 March 2026
Est. completion
2 January 2028

Where this trial is recruiting

Uganda

Primary endpoints

Incidence of adverse events (AEs); Incidence of grade 3 or greater radiotherapy-related gastrointestinal or genitourinary AEs; Local control (complete remission, stable disease, and partial response) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov